Sector News

Researchers identify new genetic clues for ‘silent’ strokes

March 27, 2021
Life sciences

New research has discovered genetic clues in people who have had small, ‘silent’ strokes that could enable the development of new treatments for the condition.

The research, funded by the British Heart Foundation (BHF), identified changes to 12 genetic regions in the DNA of people who have had a lacunar stroke – this type of stroke is caused by a weakening of the small blood vessels deep in the brain.

Following this type of stroke, damage to the blood vessels and interruption to blood flow can cause difficulty with thinking, memory, walking and ultimately lead to dementia.

Prior to this research, only one genetic fault had been associated with lacunar strokes.

The research team, led by Professor Hugh Markus and his team at the University of Cambridge working with international researchers, now hope their findings could enable the discovery of new treatments for lacunar stroke and vascular dementia.

The researchers scanned and compared the genetic code of 7,338 patients who had a lacunar stroke with 254,798 people who had not.

After this, they discovered many of the 12 genetic regions linked to lacunar strokes were involved in maintaining the neurovascular unit.

These genetic changes are believed to make the small blood vessels ‘leakier’ and cause toxic substances to enter the brain.

The research team, based on their findings, will now plan to test if new treatments can correct these abnormalities on brain cells in the lab, with hopes to begin human clinical trials in the next ten years.

“These small and often silent lacunar strokes have gone under the radar for a long time, and so we haven’t been able treat patients as well as we’d like to. Although small, their consequences for patients can be enormous,” said Professor Markus, BHF-funded researcher, leader of the study and neurologist at the University of Cambridge.

“We now plan to use this new genetic blueprint as a springboard to develop much needed treatments to prevent lacunar strokes from occurring in the first place and to help stave off dementia,” he added.

by Lucy Parsons

Source: pharmatimes.com

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).